CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 706 enrolled
Drug / intervention
HR20013 + dexamethasone + palonosetron placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06554184
NCT06554184Phase 3Completed
CompareCT.gov

A Randomized Phase III Study Evaluating the Efficacy and Safety of HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Fujian Shengdi Pharmaceutical Co., Ltd.·interventional·Posted Aug 15, 2024·Updated Nov 17, 2025

In Brief

A Phase 3 clinical trial evaluating HR20013 + dexamethasone + palonosetron placebo and Palonosetron + dexamethasone + HR20013 placebo for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents. Completed, enrolled 706 participants across 1 site.

Detailed Summary

This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20252026
First PostedAug 15, 2024
Enrollment StartSep 3, 2024
Primary CompletionJul 28, 2025
Study CompletionOct 3, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 1.9 years ago

Interventions

HR20013 + dexamethasone + palonosetron placebodrug

HR20013 + dexamethasone + palonosetron placebo

Palonosetron + dexamethasone + HR20013 placebodrug

Palonosetron + dexamethasone + HR20013 placebo